First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 47.35 CNY 0.62% Market Closed
Updated: Apr 28, 2024

Tibet Rhodiola Pharmaceutical Holding Co
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tibet Rhodiola Pharmaceutical Holding Co
Revenue Peer Comparison

Comparables:
1099
S
601607
600998
C
600511
000963

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Revenue
¥3.1B
CAGR 3-Years
32%
CAGR 5-Years
25%
CAGR 10-Years
8%
Sinopharm Group Co Ltd
HKEX:1099
Revenue
¥591.6B
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
15%
S
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Revenue
¥260.3B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
13%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Revenue
¥151.8B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
17%
C
China National Medicines Corp Ltd
SSE:600511
Revenue
¥49.7B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
17%
Huadong Medicine Co Ltd
SZSE:000963
Revenue
¥40.3B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
10%

See Also

What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue?
Revenue
3.1B CNY

Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Revenue amounts to 3.1B CNY.

What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue growth rate?
Revenue CAGR 10Y
8%

Over the last year, the Revenue growth was 23%. The average annual Revenue growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 32% over the past three years , 25% over the past five years , and 8% over the past ten years .